Skip to main content
Top
Published in: BMC Geriatrics 1/2024

Open Access 01-12-2024 | Research

Disentangling drug contributions: anticholinergic burden in older adults linked to individual medications: a cross-sectional population-based study

Authors: Gauri Bhatkhande, Niteesh K. Choudhry, Mufaddal Mahesri, Nancy Haff, Julie C. Lauffenburger

Published in: BMC Geriatrics | Issue 1/2024

Login to get access

Abstract

Background

Medications with potent anticholinergic properties have well-documented adverse effects. A high cumulative anticholinergic burden may arise from the concurrent use of multiple medications with weaker anticholinergic effects. We sought to identify patterns of high anticholinergic burden and associated patient characteristics.

Methods

We identified patients aged ≥ 65 who filled ≥ 1 medication with anticholinergic adverse effects in 2019 and had a cumulative Anticholinergic Burden score (ACB) ≥ 4 (i.e., high anticholinergic burden) in a large US health insurer. We classified patients based on how they attained high burden, as follows: 1) only filling strong or moderate anticholinergic medications (i.e., ACB = 2 or 3, “moderate/strong”), 2) only filling lightly anticholinergic medications (i.e., ACB = 1, “light/possible”), and 3) filling any combination (“mix”). We used multinomial logistic regression to assess the association between measured patient characteristics and membership in the three anticholinergic burden classifications, using the moderate/strong group as the referent.

Results

In total, 83,286 eligible patients with high anticholinergic burden were identified (mean age: 74.3 years (SD:7.1), 72.9% female). Of these, 4.5% filled only strong/moderate anticholinergics, 4.3% filled only light/possible anticholinergics, and the rest filled a mix (91.2%). Within patients in the mixed group, 64.3% of medication fills were for light/possible anticholinergics, while 35.7% were for moderate/strong anticholinergics. Compared with patients in the moderate/strong anticholinergics group, patients filling only light/possible anticholinergics were more likely to be older (adjusted Odds Ratio [aOR] per 1-unit of age: 1.06, 95%CI: 1.05–1.07), less likely to be female (aOR: 0.56, 95%CI: 0.50–0.62 vs. male), more likely to have comorbidities (e.g., heart failure aOR: 3.18, 95%CI: 2.70–3.74 or depression aOR: 1.20, 95%CI: 1.09–1.33 vs. no comorbidity), and visited fewer physicians (aOR per 1-unit of change: 0.98, 95%CI: 0.97–0.98). Patients in the mixed group were older (aOR per 1-unit of age: 1.02, 95%CI: 1.02–1.03) and less likely to be female (aOR: 0.89, 95%CI: 0.82–0.97 vs. male) compared with those filling moderate/strong anticholinergics.

Conclusion

Most older adults accumulated high anticholinergic burden through a combination of light/possible and moderate/strong anticholinergics rather than moderate/strong anticholinergics, with light/possible anticholinergics being the major drivers of overall anticholinergic burden. These insights may inform interventions to improve prescribing in older adults.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pasina L, Djade CD, Lucca U, Nobili A, Tettamanti M, Franchi C, et al. Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study. Drugs Aging. 2013;30(2):103–12.CrossRefPubMed Pasina L, Djade CD, Lucca U, Nobili A, Tettamanti M, Franchi C, et al. Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study. Drugs Aging. 2013;30(2):103–12.CrossRefPubMed
2.
go back to reference Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia: A nested case-control study. JAMA Intern Med. 2019;179(8):1084–93.CrossRefPubMedPubMedCentral Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia: A nested case-control study. JAMA Intern Med. 2019;179(8):1084–93.CrossRefPubMedPubMedCentral
3.
go back to reference Berdot S, Bertrand M, Dartigues JF, Fourrier A, Tavernier B, Ritchie K, et al. Inappropriate medication use and risk of falls–a prospective study in a large community-dwelling elderly cohort. BMC Geriatr. 2009;9:30.CrossRefPubMedPubMedCentral Berdot S, Bertrand M, Dartigues JF, Fourrier A, Tavernier B, Ritchie K, et al. Inappropriate medication use and risk of falls–a prospective study in a large community-dwelling elderly cohort. BMC Geriatr. 2009;9:30.CrossRefPubMedPubMedCentral
4.
go back to reference Cardwell K, Hughes CM, Ryan C. The association between anticholinergic medication burden and health related outcomes in the “oldest old”: a systematic review of the literature. Drugs Aging. 2015;32(10):835–48.CrossRefPubMed Cardwell K, Hughes CM, Ryan C. The association between anticholinergic medication burden and health related outcomes in the “oldest old”: a systematic review of the literature. Drugs Aging. 2015;32(10):835–48.CrossRefPubMed
5.
go back to reference Cilag J, Abbott E, Center G. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001;62(21):11–4. Cilag J, Abbott E, Center G. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001;62(21):11–4.
6.
go back to reference Block CK, Logue E, Thaler NS, Scarisbrick DM, Mahoney JJ III, Scott J, et al. The interaction between medical burden and anticholinergic cognitive burden on neuropsychological function in a geriatric primary care sample. Arch Clin Neuropsychol. 2015;30(2):105–13.CrossRefPubMed Block CK, Logue E, Thaler NS, Scarisbrick DM, Mahoney JJ III, Scott J, et al. The interaction between medical burden and anticholinergic cognitive burden on neuropsychological function in a geriatric primary care sample. Arch Clin Neuropsychol. 2015;30(2):105–13.CrossRefPubMed
7.
go back to reference Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–7.CrossRefPubMedPubMedCentral Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–7.CrossRefPubMedPubMedCentral
8.
go back to reference Mate KE, Kerr KP, Pond D, Williams EJ, Marley J, Disler P, et al. Impact of multiple low-level anticholinergic medications on anticholinergic load of community-dwelling elderly with and without dementia. Drugs Aging. 2015;32(2):159–67.CrossRefPubMed Mate KE, Kerr KP, Pond D, Williams EJ, Marley J, Disler P, et al. Impact of multiple low-level anticholinergic medications on anticholinergic load of community-dwelling elderly with and without dementia. Drugs Aging. 2015;32(2):159–67.CrossRefPubMed
9.
go back to reference Chatterjee S, Bali V, Carnahan RM, Chen H, Johnson ML, Aparasu RR. Risk of mortality associated with anticholinergic use in elderly nursing home residents with depression. Drugs Aging. 2017;34:691–700.CrossRefPubMed Chatterjee S, Bali V, Carnahan RM, Chen H, Johnson ML, Aparasu RR. Risk of mortality associated with anticholinergic use in elderly nursing home residents with depression. Drugs Aging. 2017;34:691–700.CrossRefPubMed
10.
go back to reference Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168(5):508–13.CrossRefPubMed Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168(5):508–13.CrossRefPubMed
11.
go back to reference Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The anticholinergic drug scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46(12):1481–6.CrossRefPubMed Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The anticholinergic drug scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46(12):1481–6.CrossRefPubMed
12.
go back to reference Campbell N, Maidment I, Fox C, Khan B, Boustani M. The 2012 update to the anticholinergic cognitive burden scale. J Am Geriatr Soc. 2013;61(S1):S142–3. Campbell N, Maidment I, Fox C, Khan B, Boustani M. The 2012 update to the anticholinergic cognitive burden scale. J Am Geriatr Soc. 2013;61(S1):S142–3.
14.
go back to reference Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysis. Br J Clin Pharmacol. 2015;80(2):209–20.CrossRefPubMedPubMedCentral Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysis. Br J Clin Pharmacol. 2015;80(2):209–20.CrossRefPubMedPubMedCentral
15.
go back to reference Hanlon P, Quinn TJ, Gallacher KI, Myint PK, Jani BD, Nicholl BI, et al. Assessing Risks of Polypharmacy Involving Medications With Anticholinergic Properties. Ann Fam Med. 2020;18(2):148–55.CrossRefPubMedPubMedCentral Hanlon P, Quinn TJ, Gallacher KI, Myint PK, Jani BD, Nicholl BI, et al. Assessing Risks of Polypharmacy Involving Medications With Anticholinergic Properties. Ann Fam Med. 2020;18(2):148–55.CrossRefPubMedPubMedCentral
16.
go back to reference Pfistermeister B, Tümena T, Gaßmann KG, Maas R, Fromm MF. Anticholinergic burden and cognitive function in a large German cohort of hospitalized geriatric patients. PLoS ONE. 2017;12(2): e0171353.CrossRefPubMedPubMedCentral Pfistermeister B, Tümena T, Gaßmann KG, Maas R, Fromm MF. Anticholinergic burden and cognitive function in a large German cohort of hospitalized geriatric patients. PLoS ONE. 2017;12(2): e0171353.CrossRefPubMedPubMedCentral
17.
go back to reference Krüger C, Schäfer I, van den Bussche H, Bickel H, Fuchs A, Gensichen J, et al. Anticholinergic drug burden according to the anticholinergic drug scale and the German anticholinergic burden and their impact on cognitive function in multimorbid elderly German people: a multicentre observational study. BMJ Open. 2021;11(3): e044230.CrossRefPubMedPubMedCentral Krüger C, Schäfer I, van den Bussche H, Bickel H, Fuchs A, Gensichen J, et al. Anticholinergic drug burden according to the anticholinergic drug scale and the German anticholinergic burden and their impact on cognitive function in multimorbid elderly German people: a multicentre observational study. BMJ Open. 2021;11(3): e044230.CrossRefPubMedPubMedCentral
18.
go back to reference CebronLipovec N, Jazbar J, Kos M. Anticholinergic Burden in Children, Adults and Older Adults in Slovenia: A Nationwide Database Study. Sci Rep. 2020;10(1):9337.CrossRef CebronLipovec N, Jazbar J, Kos M. Anticholinergic Burden in Children, Adults and Older Adults in Slovenia: A Nationwide Database Study. Sci Rep. 2020;10(1):9337.CrossRef
19.
go back to reference Niznik J, Zhao X, Jiang T, Hanlon JT, Aspinall SL, Thorpe J, et al. Anticholinergic Prescribing in Medicare Part D Beneficiaries Residing in Nursing Homes: Results from a Retrospective Cross-Sectional Analysis of Medicare Data. Drugs Aging. 2017;34(12):925–39.CrossRefPubMedPubMedCentral Niznik J, Zhao X, Jiang T, Hanlon JT, Aspinall SL, Thorpe J, et al. Anticholinergic Prescribing in Medicare Part D Beneficiaries Residing in Nursing Homes: Results from a Retrospective Cross-Sectional Analysis of Medicare Data. Drugs Aging. 2017;34(12):925–39.CrossRefPubMedPubMedCentral
20.
go back to reference Wong HL, Weaver C, Marsh L, Mon KO, Dapito JM, Amin FR, et al. Polypharmacy and cumulative anticholinergic burden in older adults hospitalized with fall. Aging Medicine. 2023. Wong HL, Weaver C, Marsh L, Mon KO, Dapito JM, Amin FR, et al. Polypharmacy and cumulative anticholinergic burden in older adults hospitalized with fall. Aging Medicine. 2023.
21.
go back to reference Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr. 2015;15:31.CrossRefPubMedPubMedCentral Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr. 2015;15:31.CrossRefPubMedPubMedCentral
22.
go back to reference Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749–59.CrossRefPubMedPubMedCentral Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749–59.CrossRefPubMedPubMedCentral
23.
go back to reference Amoros-Reboredo P, Soy D, Hernandez-Hernandez M, Lens S, Mestres C. Anticholinergic Burden and Safety Outcomes in Older Patients with Chronic Hepatitis C: A Retrospective Cohort Study. Int J Environ Res Public Health. 2020;17(11). Amoros-Reboredo P, Soy D, Hernandez-Hernandez M, Lens S, Mestres C. Anticholinergic Burden and Safety Outcomes in Older Patients with Chronic Hepatitis C: A Retrospective Cohort Study. Int J Environ Res Public Health. 2020;17(11).
24.
go back to reference Laura Ward M, Cooper SA, Henderson A, Stanley B, Greenlaw N, Pacitti C, et al. A study on prescriptions contributing to the risk of high anticholinergic burden in adults with intellectual disabilities: retrospective record linkage study. Ann Gen Psychiatry. 2022;21(1):41.CrossRefPubMedPubMedCentral Laura Ward M, Cooper SA, Henderson A, Stanley B, Greenlaw N, Pacitti C, et al. A study on prescriptions contributing to the risk of high anticholinergic burden in adults with intellectual disabilities: retrospective record linkage study. Ann Gen Psychiatry. 2022;21(1):41.CrossRefPubMedPubMedCentral
25.
go back to reference Landi F, Dell’Aquila G, Collamati A, Martone AM, Zuliani G, Gasperini B, et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. J Am Med Dir Assoc. 2014;15(11):825–9.CrossRefPubMed Landi F, Dell’Aquila G, Collamati A, Martone AM, Zuliani G, Gasperini B, et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. J Am Med Dir Assoc. 2014;15(11):825–9.CrossRefPubMed
26.
go back to reference West T, Pruchnicki MC, Porter K, Emptage R. Evaluation of anticholinergic burden of medications in older adults. J Am Pharm Assoc (2003). 2013;53(5):496–504. West T, Pruchnicki MC, Porter K, Emptage R. Evaluation of anticholinergic burden of medications in older adults. J Am Pharm Assoc (2003). 2013;53(5):496–504.
27.
go back to reference Green AR, Reifler LM, Boyd CM, Weffald LA, Bayliss EA. Medication profiles of patients with cognitive impairment and high anticholinergic burden. Drugs Aging. 2018;35(3):223–32.CrossRefPubMedPubMedCentral Green AR, Reifler LM, Boyd CM, Weffald LA, Bayliss EA. Medication profiles of patients with cognitive impairment and high anticholinergic burden. Drugs Aging. 2018;35(3):223–32.CrossRefPubMedPubMedCentral
28.
go back to reference Hsu WH, Huang ST, Lu WH, Wen YW, Chen LK, Hsiao FY. Impact of multiple prescriptions with anticholinergic properties on adverse clinical outcomes in the elderly: A longitudinal cohort study in Taiwan. Clin Pharmacol Ther. 2021;110(4):966–74.CrossRefPubMed Hsu WH, Huang ST, Lu WH, Wen YW, Chen LK, Hsiao FY. Impact of multiple prescriptions with anticholinergic properties on adverse clinical outcomes in the elderly: A longitudinal cohort study in Taiwan. Clin Pharmacol Ther. 2021;110(4):966–74.CrossRefPubMed
29.
go back to reference Rhee TG, Choi YC, Ouellet GM, Ross JS. National prescribing trends for high-risk anticholinergic medications in older adults. J Am Geriatr Soc. 2018;66(7):1382–7.CrossRefPubMedPubMedCentral Rhee TG, Choi YC, Ouellet GM, Ross JS. National prescribing trends for high-risk anticholinergic medications in older adults. J Am Geriatr Soc. 2018;66(7):1382–7.CrossRefPubMedPubMedCentral
30.
go back to reference Reppas-Rindlisbacher CE, Fischer HD, Fung K, Gill SS, Seitz D, Tannenbaum C, et al. Anticholinergic drug burden in persons with dementia taking a cholinesterase inhibitor: The effect of multiple physicians. J Am Geriatr Soc. 2016;64(3):492–500.CrossRefPubMedPubMedCentral Reppas-Rindlisbacher CE, Fischer HD, Fung K, Gill SS, Seitz D, Tannenbaum C, et al. Anticholinergic drug burden in persons with dementia taking a cholinesterase inhibitor: The effect of multiple physicians. J Am Geriatr Soc. 2016;64(3):492–500.CrossRefPubMedPubMedCentral
31.
go back to reference Markland AD, Richter HE, Fwu CW, Eggers P, Kusek JW. Prevalence and trends of urinary incontinence in adults in the United States, 2001 to 2008. J Urol. 2011;186(2):589–93.CrossRefPubMedPubMedCentral Markland AD, Richter HE, Fwu CW, Eggers P, Kusek JW. Prevalence and trends of urinary incontinence in adults in the United States, 2001 to 2008. J Urol. 2011;186(2):589–93.CrossRefPubMedPubMedCentral
32.
go back to reference Barry LC, Allore HG, Guo Z, Bruce ML, Gill TM. Higher burden of depression among older women: the effect of onset, persistence, and mortality over time. Arch Gen Psychiatry. 2008;65(2):172–8.CrossRefPubMedPubMedCentral Barry LC, Allore HG, Guo Z, Bruce ML, Gill TM. Higher burden of depression among older women: the effect of onset, persistence, and mortality over time. Arch Gen Psychiatry. 2008;65(2):172–8.CrossRefPubMedPubMedCentral
33.
go back to reference Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018;361. Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018;361.
34.
go back to reference Green AR, Reifler LM, Bayliss EA, Weffald LA, Boyd CM. Drugs contributing to anticholinergic burden and risk of fall or fall-related injury among older adults with mild cognitive impairment, dementia and multiple chronic conditions: a retrospective cohort study. Drugs Aging. 2019;36(3):289–97.CrossRefPubMedPubMedCentral Green AR, Reifler LM, Bayliss EA, Weffald LA, Boyd CM. Drugs contributing to anticholinergic burden and risk of fall or fall-related injury among older adults with mild cognitive impairment, dementia and multiple chronic conditions: a retrospective cohort study. Drugs Aging. 2019;36(3):289–97.CrossRefPubMedPubMedCentral
35.
go back to reference Reeve E. Deprescribing tools: a review of the types of tools available to aid deprescribing in clinical practice. J Pharm Pract Res. 2020;50(1):98–107.CrossRef Reeve E. Deprescribing tools: a review of the types of tools available to aid deprescribing in clinical practice. J Pharm Pract Res. 2020;50(1):98–107.CrossRef
Metadata
Title
Disentangling drug contributions: anticholinergic burden in older adults linked to individual medications: a cross-sectional population-based study
Authors
Gauri Bhatkhande
Niteesh K. Choudhry
Mufaddal Mahesri
Nancy Haff
Julie C. Lauffenburger
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue 1/2024
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-023-04640-4

Other articles of this Issue 1/2024

BMC Geriatrics 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine